Partridge Andrew John
Insider CIK 1758838 · TPTX EVP & Chief Commercial Officer · GRAL Chief Growth Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| GRAL GRAIL, Inc. | S Sale | 2026-10-05 | 2026-10-07 | 7,873 | $146.39 | $1.15M | 155,865 | SEC↗ |
| GRAL GRAIL, Inc. | S Sale | 2026-06-04 | 2026-06-05 | 1,491 | $61.08 | $91.1K | 163,738 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2022-02-09 | 2022-02-11 | 58,600 | — | $0 | 58,600 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award | 2022-02-09 | 2022-02-11 | 16,283 | — | $0 | 38,361 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2022-02-09 | 2022-02-11 | 221 | $36.30 | $8.0K | 22,078 | SEC↗ |
| TPTX Turning Point Therapeutics | S Sale | 2021-07-14 | 2021-07-15 | 1,869 | $74.90 | $140.0K | 21,767 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2021-02-08 | 2021-02-10 | 9,733 | — | $0 | 9,733 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award | 2021-02-08 | 2021-02-10 | 2,136 | — | $0 | 23,636 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award deriv | 2020-07-13 | 2020-07-14 | 127,500 | — | $0 | 127,500 | SEC↗ |
| TPTX Turning Point Therapeutics | A Award | 2020-07-13 | 2020-07-14 | 21,500 | — | $0 | 21,500 | SEC↗ |